This Event is licensed under the Creative Commons BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Event: 1489
Key Event Title
N/A, Steatohepatisis
Short name
Biological state: steatohepatisis is steatosis (fatty liver) presenting with inflammation.
Biological compartment: liver.
Role in biology: Steatohepatisis is a disease and adverse endpoint. If this state continues, it will eventually lead to fibrosis and cirrhosis of the liver.
Steatohepatitis is typically measured histologically. Fatty liver is noticed by oil red O staining, although it also may be noted using lipidomics. Inflammatory cell infiltration is typically noted histologically.
| ID | Experimental Effect | Biological Object | Biological Process | Method of Measurement | Notes | Evidence Source ID | Citation (first author, year) |
|---|
| ID | Stressor | Sample (short_name) | Assay | Effect |
|---|
| Level of Biological Organization |
|---|
| Organ |
Organ term
AOPs Including This Key Event
| AOP Name | Role of event in AOP | Point of Contact | Author Status | OECD Status |
|---|---|---|---|---|
| Inhibition fatty acid beta oxidation leading to nonalcoholic steatohepatisis (NASH) | AdverseOutcome | Arthur Author (send email) | Open for adoption | |
| endocrine disrupting effect | AdverseOutcome | Agnes Aggy (send email) | Under development: Not open for comment. Do not cite |
Taxonomic Applicability
| Term | Scientific Term | Evidence | Link |
|---|---|---|---|
| Vertebrates | Vertebrates | High | NCBI |
Life Stages
| Life stage | Evidence |
|---|---|
| All life stages | High |
Sex Applicability
| Term | Evidence |
|---|---|
| Unspecific | High |
NASH (non-alcoholic steatohepatitis) can occur in any organism that contains a liver.
The precursor state to NASH (non-alcoholic steatohepatitis), steatosis, has been used in US EPA IRIS assessments as an adverse outcome.